ConforMIS Inc (NASDAQ:CFMS)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity in a research report issued to clients and investors on Tuesday, MarketBeat.Com reports. They presently have a $26.00 target price on the stock. Canaccord Genuity’s target price suggests a potential upside of 138.31% from the company’s current price.

A number of other equities analysts also recently issued reports on CFMS. Zacks Investment Research upgraded shares of ConforMIS from a “sell” rating to a “hold” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. set a $23.00 price objective on shares of ConforMIS and gave the company an “overweight” rating in a research note on Monday, January 4th. Oppenheimer reissued a “buy” rating and issued a $25.00 price objective on shares of ConforMIS in a research note on Wednesday, November 11th. Finally, Sterne Agee CRT began coverage on shares of ConforMIS in a research note on Tuesday, December 1st. They issued a “buy” rating and a $26.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. ConforMIS currently has a consensus rating of “Buy” and an average target price of $25.40.

Shares of ConforMIS (NASDAQ:CFMS) opened at 10.91 on Tuesday. ConforMIS has a 1-year low of $9.55 and a 1-year high of $26.93. The stock’s market capitalization is $444.17 million. The stock has a 50 day moving average of $15.14 and a 200-day moving average of $18.89.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.07. The firm had revenue of $13.90 million for the quarter, compared to analyst estimates of $13.51 million. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. Equities research analysts predict that ConforMIS will post ($3.75) earnings per share for the current fiscal year.

Other large investors have recently added to or reduced their stakes in the company. Stanhope Investments purchased a new stake in ConforMIS during the fourth quarter valued at about $27,015,000. California State Teachers Retirement System boosted its stake in ConforMIS by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 19,171 shares of the company’s stock valued at $331,000 after buying an additional 271 shares in the last quarter. Finally, Simplex Trading purchased a new stake in ConforMIS during the fourth quarter valued at about $0.

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, to fit each patient’s anatomy. It is engaged in offering a line of customized knee implants designed to restore the natural shape of a patient’s knee. The Company has sold over 30,000 knee implants in the United States and Europe. It also launched iTotal PS, the Company’s posterior-stabilized total knee replacement implant, which addresses the largest segment of the knee replacement market. The Company’s products are available in the United States, Germany and the United Kingdom. Its products are offered to orthopedic surgeons, hospitals and other medical facilities and patients. The Company’s iFit technology platform includes three elements: iFit Design, iFit Printing and iFit Just-in-Time Delivery.

12 Month Chart for NASDAQ:CFMS

Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.